Altimmune announced its Q2 2025 financial results, reporting a net loss of $22.1 million and a net loss per share of $0.27. The company's cash, cash equivalents, and short-term investments increased to $183.1 million. Key highlights include positive 24-week data from the IMPACT Phase 2b trial for pemvidutide in MASH, with significant MASH resolution and weight loss, and the initiation of two new Phase 2 trials for pemvidutide in Alcohol Use Disorder and Alcohol-Associated Liver Disease.
Pemvidutide's IMPACT Phase 2b trial showed statistically significant MASH resolution in up to 59.1% of patients and up to 6.2% weight loss at 24 weeks.
New data from the IMPACT trial demonstrated potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis.
Altimmune reported a net loss of $22.1 million for Q2 2025, an improvement from $24.6 million in the same period last year.
Cash, cash equivalents, and short-term investments significantly increased to $183.1 million as of June 30, 2025, up 39% from December 31, 2024.
Altimmune anticipates several key milestones in the coming quarters, primarily focused on advancing pemvidutide through clinical development for MASH, AUD, and ALD.
Analyze how earnings announcements historically affect stock price performance